Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer

Clinical Immunology

Volumn 111, Issue 1, 2004, Pages 69-81

  Reome, Joyce B ^a   Hylind, James C ^a   Dutton, Richard W ^a   Dobrzanski, Mark J ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

CD3 DX5; CD8+ or CD4+T cells producing type 1 cytokines; CD8+ or CD4+T cells producing type 2 cytokines; Chemokines; Cytokines; NK cells; Tc1 Th1; Tc2 Th2; Th1 Tc1; Th2 Tc2 TIL cells; Tumor evasion; Tumor immunity

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER STAGING; CELL MATURATION; CELL SUBPOPULATION; CELL SURFACE; CELL TYPE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOREGULATION; KINETICS; MAMMARY GLAND; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE; TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; UPREGULATION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; TH1 CELLS; TH2 CELLS;

EID: 1842735268     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2003.11.013     Document Type: Article

References (59)

1. Schmitt C.A. Senescence, apoptosis and therapy-cutting the life lines of cancer. 2003. Nat. Rev., Cancer. 3:2003;286-295.
2. Bissell M.J., Radisky D. Putting tumors in context. Nat. Rev., Cancer. 1:2001;46-54.
3. Singh S., Ross S.R., Acena M., Rowley D.A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:1992;139-146.
4. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., Fu Y.X., Schreiber H. Increasing tumor antigen expression overcomes ignorance to solid tumors via cross presentation by bone marrow-derived stromal cells. Immunity. 17:2002;737-747.
5. Yee C., Greenberg P. Modulating T cell immunity to tumors: new strategies for monitoring T cell responses. Nat. Rev., Cancer. 2:2002;409-420.
6. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1992;1795-1798.
7. Correa M.R., Ochoa A.C., Ghosh P., Mizoguchi H., Harvey L., Longo D.L. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158:1997;5292-5296.
8. Speiser D.E., Pittet M.J., Dunbar R., Rimoldi D., Lienard D., Robson Mcdonald H., Cerundolo J., Romero P. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190:1999;775-782.
9. Moser J.M., Gibbs J., Jensen P.E., Lukacher A.E. CD94-NKG2A receptors regulate antiviral CD8 T cell responses. Nat. Immunol. 3:2002;189-195.
10. Deeths M.J., Kedl R.M., Mescher M.F. CD8 T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163:1999;102-110.
11. Torre-Amione G.et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. 87:1990;1486-1490.
12. Croft M.L., Carter L.L., Swain S.L., Dutton R.W. Generation of polarized antigen specific CD8 effector populations: reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1994;1715-1721.
13. Carter L.L., Dutton R.W. Type 1 and Type 2: a fundamental dichotomy for all T cell subsets. Curr. Opin. Immunol. 8:1996;336-340.
14. Sad S., Marcotte R., Mosmann T.R. Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting Th1 or Th2 cytokines. Immunity. 2:1995;271-277.
15. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:1999;6671-6680.
16. Dobrzanski M.J., Reome J.B., Dutton R.W. Type 1 and type 2 CD8 effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumors. J. Immunol. 164:2000;916-925.
17. Hung K., Hayashi A., Lafond-Walker A., Lowenstein C., Pardoll D., Lavitsky H. The central role of CD4 T cells in the antitumor immune response. J. Exp. Med. 12:1998;2357-2364.
18. Smyth M.J., Crowe N.Y., Hayakawa Y., Takeda K., Yagita H., Godfrey D.I. NKT cells - Conductors of tumor immunity? Curr. Opin. Immunol. 14:2002;165-171.
19. Nanni P., de Giovanni C., Lollini P.L., Prodi G. TS/A: a new metastasizing cell line from BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis. 4:1983;373-380.
20. Dutton R.W., Bradley L.M., Swain S.L. T cell memory. Annu. Rev. Immunol. 16:1998;201-214.
21. Dobrzanski M.J., Reome J.B., Dutton R.W. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J. Immunol. 167:2001;424-434.
22. Dobrzanski M.J., Reome J.B., Dutton R.W. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98:2001;70-84.
23. Homey B., Muller A., Zlotnik A. Chemokines: agents for immunotherapy of cancer. Nat. Rev., Immunol. 2:2002;175-187.
24. Hudson J.D., Shoaibi M.A., Maestro R., Carnero A., Hannon G.J., Beach D.H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190:1999;1375-1382.
25. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., Zinkernagel R.M. Roles of tumor localization second signals and cross priming in cytotoxic T cell induction. Nature. 411:2001;1058-1063.
26. Staveley-O'Carrol K.E., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H. Induction of antigen-specific T cell anergy: early events in the course of tumor progression. Proc. Natl. Acad. Sci. 95:1998;1178-1186.
27. Stutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:2001;823-832.
28. Kacha A.K., Fallarino F., Markiewicz M.A., Gakewski T.F. Cutting edge: spontaneous rejection of poorly immunogenic P1. HTR tumors by stat6-deficient mice. J. Immunol. 165:2000;6024-6028.
29. Hu H.M., Urba W.J., Fox B.A. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell responses from type 2 to a type 1 cytokine profile. J. Immunol. 161:1998;3033-3041.
30. Jensen S.M., Meijer S.L., Kurt R.A., Urba W.J., Hu H.M., Fox B. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of stat 6-reactive T cells. J. Immunol. 170:2003;2014-2021.
31. Winter H., Hu H.M., Poehlein C.H., Huntzicker E., Osterholzer J.J., Bashy J., Lashley D., Lowe B., Yamada J., Alvord G., Urba W.J., Fox B.A. Tumor-induced polarization of tumor vaccine-draining lmph node T cells to type 1 cytokine profiles predict inherent strong immunogenicity of the tumor and correlates with therapeutic efficacy in adoptive transfer studies. Immunology. 108:2003;409-419.
32. Ostrand-Rosenberg S., Grusby M.J., Clements V.K. Cutting edge: stat6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:2000;6015-6019.
33. Bosco M., Giovarelli M., Forni M., Modesti A., Scarpa S., Masuelli L., Forni G. Low dose of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145:1990;3136-3143.
34. Pericle F., Giovarelli M., Columbo M.P., Ferrari G., Musiani P., Modesti A., Cavallo F., Di Pierro F., Novelli F., Forni G. An efficient Th2 type memory follows CD8 lymphocyte driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153:1994;5659-5673.
35. Modesti A., Masuelli L., Modica A., D'Orazi G., Scarpa S., Bosco M.C., Forni G. Ultrastructural evidence of the mechanisms responsible for IL-4-activated rejection of a spontaneous murine adenocarcinoma. Int. J. Cancer. 53:1992;988-993.
36. Hamilton T.A., Tannenbaum C.S., Finke J., Bukowski R. Interaction between chemokines and other cytokines in host responses to tumor. Rollins B.J. Chemokines and Cancer. 1999;115-136 Humana Press Inc. Totowa, NJ.
37. Slifka M.K., Lindsay Whitton J. Antigen-specific regulation of T cell-mediated cytokine production. Immunity. 12:2000;451-461.
38. Hu H.M., Winter H., Urba W.J., Fox B.A. Divergent roles for CD4 T cells in the priming and effector/memory phases of adoptive therapy. J. Immunol. 165:2000;4246-4253.
39. Bronte V., Serafini P., Mazzoni A., Segal D.M., Zanovello P. L-arginine metabolism in myeloid cells controls T lymphocyte functions. Trends Immunol. 24:2003;302-306.
40. Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., Segal D.M., Staib C., Lowel M., Sutter G., Colombo M.P., Zanovello P. IL-4 induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170:2003;270-278.
41. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b/Gr-1/CD31 myeloid progenitor capable of activating or suppressing CD8 T cells. Blood. 96:2000;3838-3846.
42. North R.J. Downregulation of the antitumor immune response. Adv. Cancer Res. 45:1985;1-43.
43. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.R., Kaiser L.R., June C.H. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168:2002;4272-4276.
44. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., June C.H. Regulatory CD4CD25 T cells in tumors from patients with early stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res. 61:2001;4766-4774.
45. Piccirillo C.A., Shevach E.M. Cutting edge: control of CD8 T cell activation by CD4CD25 immunoregulatory cells. J. Immunol. 167:2001;1137-1141.
46. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25CD4 T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:1999;5211-5218.
47. Moodycliff A.M., Nghiem D., Clydesdale G., Ullrich S.E. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1:2000;521-525.
48. Tamaga K., Harada M., Abe K., Li T., Tada H., Onoe Y., Nomoto K. Immunosuppressive activity of cloned natural killer T cells established from murine tumor infiltrating lymphocytes. J. Immunol. 158:1997;4846-4854.
49. Smyth M.J., Thia K.Y.T., Street S.E.A., Cretney E., Trepani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Gofrey D.I. Differential tumor surveillance by natural killer and NKT cells. J. Exp. Med. 191:2000;661-668.
50. Gorelik L., Flavell R.A. Immune-mediated eradication of tumor through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:2001;1118-1126.
51. Abe R., Peng T., Sailors J., Bucala R., Metz C.N. Regulation of the CTL response by macrophage migration inhibitory factor. J. Immunol. 166:2001;747-753.
52. Mitchell R.A., Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Cancer Biol. 10:2000;359-366.
53. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., Gemsa D., Donnelly T., Bucala R. An essential regulatory role for macrophage inhibitory factor in T cell activation. Proc. Natl. Acad. Sci. 93:1996;7849-7854.
54. Repp A.C., Mayhew E.S., Apte S., Niederkorn J.Y. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165:2000;710-715.
55. Giovarelli M., Cappello P., Forni G., Salcedo T., Moore P.A., LeFleur D.W., Nardelli B., Di Carlo E., Lollini P., Ruben S., Ullrich S., Garotta G., Musiani P. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes and granulocytes. J. Immunol. 164:2000;3200-3212.
56. Siveke J.T., Hamann A. Cutting edge: T helper 1 and T helper 2 cells respond differentially to chemokines. J. Immunol. 160:1998;550-554.
57. Poznansky M.C., Olszak I.T., Foxall R., Evans R.H., Luster A.D., Scadden D.T. Active movement of T cells away from a chemokine. Nat. Med. 6:2000;543-548.
58. Hodge D.L., Schill W.B., Wang J.M., Blanca I., Reynolds D.A., Ortaldo J.R., Young H.A. IL-2 and IL-12 alter NK cell responsiveness to IFN-γ-inducible protein 10 by down regulating CXCR3 expression. J. Immunol. 168:2002;6090-6098.
59. Nesbit M., Schaider H., Miller T.H., Herlyn M. Low level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in non-tumorigenic melanoma cells. J. Immunol. 166:2001;6483-6490.